Discovery & history

• Where BPC-157 came from and what the "body protection compound" story actually means
• The mechanisms it is proposed to touch, from the NO system to FAK-paxillin signaling
• How to weigh a literature dominated by a single research lineage
• What the regulatory status (WADA, FDA 503A) and safety evidence really say

1. 01 Discovery & history A fragment of gastric juice that grew an outsized reputation free
2. 02 The molecule and its structure Fifteen residues, four prolines, and a famous stability claim paid
3. 03 Vascular mechanisms: nitric oxide and angiogenesis The two vascular stories BPC-157 tells best paid
4. 04 Growth-factor and kinase signaling The signaling behind the healing claims paid
5. 05 Gut healing: the original domain Where the BPC-157 story actually began paid
6. 06 Tendon and ligament repair The cleanest mechanistic story, and the one most over-sold to athletes paid
7. 07 Skin and wound healing Faster, better-organized skin repair, in rodents paid
8. 08 Nerve, brain, and beyond The broad, speculative end of the BPC-157 story paid
9. 09 Dosing & Administration What the community does, and why none of it is a protocol paid
10. 10 Safety & regulatory status A reassuring preclinical package, a near-empty human record, and a hard legal line paid
11. 11 Reading the evidence honestly An unusually deep preclinical story with an unusually shallow clinical base paid
12. 12 Final Exam & Certification Pass the final exam to earn your certificate of completion. Exam

BPC-157 did not come from a drug-design program. It came from the idea that the stomach protects itself, and that the molecules doing the protecting might help the rest of the body too. The Zagreb group proposed the stomach as the starting point of a whole-body protective response, and described BPC-157 as a 15-amino-acid fragment of a gastric-juice peptide, "thought to be essential for its activity".

Notice what is missing from that timeline: an adequately reported human efficacy result. One randomized placebo-controlled efficacy study does exist, in ulcerative colitis, and it matters that it is not a blank: it ran, it reported, it did not separate from placebo, and it never went beyond a 2005 meeting abstract that FDA later judged inadequate. Put plainly: no adequately reported randomized human efficacy trial has ever read out, for any indication. That mismatch is the throughline of this whole course.

Strip away the marketing and BPC-157 is a short chain of fifteen amino acids. The founding paper describes it as a fragment of a gastric-juice peptide, thought to be essential for that peptide's activity, and USADA states that the BPC-157 sold online or through compounding pharmacies is all synthetically produced. What people buy is a made copy of that fragment, not something extracted from the body.

The full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. A 2026 review attributes its reported stability most plausibly to the rigid run of three prolines at positions 3 to 5, though no source in this course tests that explanation.

BPC-157 is sold in the same "recovery peptide" niche as a few others. Seeing them side by side clarifies what is actually distinctive about it, and where it is simply less characterized than the alternatives. One note on sourcing: the three comparator rows below are drawn from the separate TB-500, GHK-Cu and KPV courses and their own source files, not from the BPC-157 literature, so treat them as orientation and read those courses for the detail. Only the BPC-157 row and the closing point are sourced here.

The pattern is revealing. BPC-157 has the widest range of preclinical claims but the least defined molecular target: the FDA states outright that its molecular targets have not been identified, while TB-500's parent binds actin, GHK-Cu is a copper complex, and KPV enters cells through a named transporter. The comparator rows come from the other courses; for BPC-157 itself, no controlled human efficacy trial in athletic soft-tissue recovery, the use it is marketed for, has reported. A hamstring-strain trial (NCT07437547) is recruiting and a rotator cuff repair trial (NCT07803250) is not yet recruiting; neither has results.

The most important thing to understand before any mechanism slide is where the evidence comes from. A 2026 review put a number on it: by author-affiliation analysis, more than 80% of the BPC-157 literature originates from a single research group at the University of Zagreb. A 2025 systematic review grades the whole body as level IV and level V evidence, the lowest tiers there are.

This is not an accusation that the work is wrong. It is a reminder that science gains confidence through independent replication, and that a field built largely by one group has not yet earned that confidence. Keep this caveat in mind every time a later unit describes a mechanism or a healing result.

Before the deeper science, here is the honest map of what is well supported versus merely hopeful. The point of this course is to keep these tiers apart instead of rounding everything up to "proven."

The gap between the green tiers and the red ones is the entire subject of this course. The rat-level mechanism work is genuinely substantial, and that is exactly why honest framing matters: a strong preclinical story is the easiest kind to over-sell as a human result.

A few specific claims you will meet online, held against the evidence tiers above. Most are not flatly false, they are real but modest preclinical findings rounded up into certainty.

Reading each claim against its actual tier is the core skill this course builds. By the final exam you should be able to take any BPC-157 marketing sentence and place it on this map yourself.